| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
AbCellera Biologics (NASDAQ:ABCL) reported its Q4 earnings results on Tuesday, February 20, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
AbCellera Biologics missed estimated earnings by 30.77%, reporting an EPS of $-0.17 versus an estimate of $-0.13.
Revenue was down $12.37 million from the same period last year.
Last quarter the company beat on EPS by $0.03 which was followed by a 6.09% increase in the share price the next day.
Here's a look at AbCellera Biologics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.13 | -0.13 | -0.14 | 0 |
| EPS Actual | -0.10 | -0.11 | -0.14 | -0.1 |
| Revenue Estimate | 11.90M | 12.37M | 12.11M | 50.80M |
| Revenue Actual | 6.60M | 10.06M | 12.19M | 21.55M |
To track all earnings releases for AbCellera Biologics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ABCL
